In Vitro Susceptibility of HCV Genotype 1 Through 6 Clinical Isolates to the Pan-Genotypic NS3/4A Inhibitor Voxilaprevir

Journal of Clinical Microbiology - United States
doi 10.1128/jcm.01844-18
Full Text
Abstract

Available in full text

Categories
Microbiology
Date
Authors
Publisher

American Society for Microbiology

Related search

HCV NS3/4A Protein Complex

Science-Business eXchange
2012English

Structural and Thermodynamic Effects of Macrocyclization in HCV NS3/4A Inhibitor MK-5172

English

In Vitro Antiviral Profile of Ruzasvir: A Potent and Pan-Genotype Inhibitor of HCV NS5A

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2018English

Editorial: Genotype 3 HCV-who Still Needs Ribavirin in a Pan-Genotypic Era?

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2018English

Editorial: Genotype 3 HCV-who Still Needs Ribavirin in a Pan-Genotypic Era? Authors’ Reply

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2018English

Metalloprotoporphyrin Inhibition of HCV NS3-4A Protease: Structure–Activity Relationships

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2020English

Drug Resistance Against HCV NS3/4A Inhibitors Is Defined by the Balance of Substrate Recognition Versus Inhibitor Binding

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2010English

Sofosbuvir and Velpatasvir: A Complete Pan-Genotypic Treatment for HCV Patients

Turkish Journal of Gastroenterology
Gastroenterology
2016English

Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections

Gastroenterology
HepatologyGastroenterology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy